News Releases

Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2024
REDWOOD CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU),

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

May 13, 2024
Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024 Company to Host Key Opinion Leader Webinar on the Potential of Briquilimab in Asthma on May 20, 2024, at 8:00 a.m. EDT REDWOOD CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) --

Jasper Therapeutics to Present at Upcoming Investor Conferences in May

May 7, 2024
REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU)
Displaying 1 - 10 of 19
Top

External Link

You are now leaving the Jasper Therapeutics, Inc. site to a 3rd party website. Jasper Therapeutics is not responsible for 3rd party website content.